Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Google Secures Pentagon AI Deal for Classified Projects 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DURHAM, N.C., May 02, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 3258363. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
